The EANM Journal
Издатель: Elsevier · ISSN 3051-2921 · 24 статей
- From fixed dosing to personalised medicine: evaluating personalisation strategies in systemic targeted radionuclide therapies
- Celebrating 85 years of radioiodine: Saul Hertz and the foundations of theranostic precision medicine
- EANM 2025 editors’ choices
- The 6th Chinese academic symposium on PET/MR: Updates of clinical practice and existing challenges
- PSMA PET is no longer a matter of evidence, but a matter of access and sustainability: Insights from an Italian multidisciplinary survey in a European perspective
- 50 years with FDG PET: The warm-up
- The need for quantitative analysis in the baseline assessment and follow-up of AD patients undergoing anti-amyloid treatments
- Images saves lives: The EU Safe Hearts Plan
- Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients
- [68Ga]Ga-OncoACP3 PET imaging defines acid phosphatase 3 as a clinically actionable theranostic target in prostate cancer: a prospective phase I trial
- An investigation of the APOE4 association with tau pathology and cognitive decline
- FDG PET/CT beyond mismatch exclusion in [177Lu]Lu-PSMA therapy: baseline prognosis and response assessment
- Nationwide phantom evaluation of real-world amyloid PET imaging in Japan under the Japanese Society of Nuclear Medicine qualification program required for reimbursement
- Trop2 immunoPET/CT in annotating differential Trop2 expression in lung cancers: a prospective clinical study
- Hybrid multi-timepoint/single-timepoint imaging for multi-cycle radiopharmaceutical therapy dosimetry: Performance in [177Lu]Lu-DOTATATE PRRT
- Which SUV is more stable for PSMA-positivity thresholding? EARL harmonized lesional SUV versus reference tissue SUV
- Simultaneous multitracer positron emission tomography: From methodology to clinical applications
- Updated procedural guideline/procedure standard [18F]FDG-PET/CT(A) in large vessel vasculitis and polymyalgia rheumatica of the EANM, SNMMI, ASNC, CANM, ANZSNM and endorsed by the CSNM
- 68Ga-PSMA-11 PET/CT in Selected Non-Prostatic Malignancies: Results from the Prospective Monocentric MORE-PSMA Registry
- Regulatory and organisational barriers to non-commercial clinical trials in European nuclear medicine: Results from an EANM survey
- [64Cu]Cu-NODAGA-PSMA-617 targeted prostate cancer PET imaging: From radiotracer development to initial clinical PET imaging at early and late time points
- Imaging more, changing nothing: Are there predictors of unchanged management after [18F]PSMA-1007 PET/CT in primary staging of high-risk prostate cancer?
- European Association of Nuclear Medicine (EANM) Focus Meeting 7: Consensus on the role of molecular imaging and fluid biomarkers in diagnosis, treatment eligibility, and monitoring in Alzheimer's Disease
- Corrigendum to “Nationwide phantom evaluation of real-world amyloid PET imaging in Japan under the Japanese society of nuclear medicine qualification program required for reimbursement” [The EANM J 4 September (2026) 100239]